Shareholder Class Action Investigation

Candel Therapeutics, Inc. NASDAQ: CADL

Henzel Law is investigating a potential shareholder class action against Candel Therapeutics over its statements that the Biologics License Application for aglatimagene was planned for the fourth quarter of 2026, after the company moved that filing to the middle of 2027 and the stock fell sharply on November 13, 2026.

← Current Cases · SPAC-Warrant Cases · Under Investigation · Case Archive

Status
Investigating — no lawsuit filed
Estimated investigation period
March 12, 2026 to November 12, 2026
Ticker
NASDAQ: CADL

What we’re investigating

Candel Therapeutics, Inc. (NASDAQ: CADL) is a Delaware company headquartered in Needham, Massachusetts that develops viral immunotherapies for cancer. Its lead product candidate, aglatimagene, is in development for localized prostate cancer.

Henzel Law is investigating whether Candel and certain of its officers made materially false or misleading statements about the timing of the Biologics License Application for aglatimagene, and whether the company sold stock to the public while that timing was in doubt. No lawsuit has been filed. This page describes an investigation.

What the company told investors

Candel told investors repeatedly, and in writing, that it planned to submit the application in the fourth quarter of 2026. In its full-year 2025 results release on March 12, 2026, the company stated that it “plans to submit a Biologics License Application (BLA) for aglatimagene … in Q4 2026,” and its chief executive officer was quoted saying the company “continue[s] to work toward a planned BLA submission in Q4 2026.” The same target appeared under the release’s “Anticipated Milestones.”

The company repeated the target five months later. In its second-quarter results release on August 13, 2026, under “Anticipated Milestones,” Candel stated that submission of the application “is planned for Q4 2026.” The same release described a newly hired chief commercial officer as strengthening the company’s efforts toward its “planned BLA submission in the fourth quarter of 2026,” and described a manufacturing campaign as “a critical CMC activity to enable the anticipated BLA submission in Q4 2026.”

The November 12, 2026 disclosure

After the market closed on November 12, 2026, Candel issued its third-quarter results. In that release the company disclosed that it was “in ongoing dialogue with the FDA regarding the submission of a Biologics License Application (BLA)” and that “[d]ue to timelines associated with certain assay refinement, the Company currently plans to submit this BLA … in the middle of 2027 pending the result of that dialogue.” The target had moved by roughly two to three quarters.

The same evening, the company announced a new agreement with a sales agent permitting it to sell up to $50 million of additional common stock in at-the-market transactions.

Candel’s stock, which had closed at $8.39 on November 12, 2026, fell to $6.20 on November 13, 2026, a decline of $2.19 per share, or approximately 26.1%. The stock traded down as much as 38% to 39% in after-hours trading on November 12, 2026.

The company’s own stock sales

The investigation is also examining Candel’s sales of its own stock during the period in which it was publishing the fourth-quarter 2026 target. In February 2026 the company completed a registered underwritten public offering of 18,348,624 shares at $5.45 per share, raising approximately $100 million in gross proceeds. Separately, Candel sold shares through an at-the-market program throughout 2026 — approximately 4.9 million shares for roughly $48.5 million in net proceeds in the first nine months of the year, including approximately 2.1 million shares for roughly $24.1 million in net proceeds during the third quarter of 2026 alone, at an average price of roughly $11.44 per share.

Shareholders who purchased in a registered offering may have claims under Sections 11 and 12(a)(2) of the Securities Act of 1933. Unlike a claim under Section 10(b) of the Securities Exchange Act of 1934, those claims do not require proof that the defendant acted with an intent to deceive.

Insider sales

Public filings show that on September 10 and 11, 2026 the company’s president and chief executive officer sold a total of 280,245 shares for gross proceeds of approximately $3.16 million, at weighted average prices of $11.4997 and $10.4564 per share. Those sales were reported as made under a Rule 10b5-1 trading plan adopted on March 13, 2026 — one day after the March 12, 2026 release that set the fourth-quarter 2026 target — and modified on June 11, 2026.

What the investigation is examining

Whether Candel’s statements that the application was planned for the fourth quarter of 2026 were accurate when made, and when the company first learned that assay refinement work would push the submission into 2027; whether the registration statement and prospectus materials used in the February 2026 offering, and in the company’s at-the-market sales during 2026, contained untrue statements of material fact or omitted material facts; whether the timing of the chief executive officer’s September 2026 stock sales, and the June 11, 2026 modification of the plan under which they were made, bear on what management knew; and whether the company’s disclosures about its dialogue with the FDA were adequate.

Who this may affect

Henzel Law is interested in hearing from individual shareholders who bought Candel Therapeutics (CADL) stock during the period under review and lost money, and from long-term shareholders who still hold their shares. We are not seeking institutional investors. If you bought shares and lost money, or if you have held shares for a long period and want the conduct described above looked into on the company’s behalf, we would like to hear from you. There is no charge for a case review and no obligation.

Free Case Evaluation

Tell us about your Candel Therapeutics (CADL) holdings. If you do not know every detail, send what you have.

Your information

The stock your question is about.

Your transactions

Add each buy, sell, exercise, assignment, or conversion separately. Add as many as you need.

No transactions added yet.

Do you currently own the stock?

Fields marked with an asterisk are required. Everything else is optional.

General enquiry

Have a question about this investigation that isn't covered above? Send a message and we will get back to you.

Fields marked with an asterisk are required.